Cardiac function and disease: Emerging role of small ubiquitin-related modifier

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 3, Issue 4, 2011, Pages 446-457

  Wang, Jun ^a  

^a TEXAS HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUMO PROTEIN;

AMINO ACID SEQUENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; HEART; HEART MUSCLE; HUMAN; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; HEART; HUMANS; MOLECULAR SEQUENCE DATA; MYOCARDIUM; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS;

EID: 79958220238     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.130     Document Type: Review

References (127)

1. Pickart CM. Back to the future with ubiquitin. Cell 2004, 116:181-190.
2. Wilkinson KD, Ventii KH, Friedrich KL, Mullally JE. The ubiquitin signal: assembly, recognition and termination. Symposium on ubiquitin and signaling. EMBO Rep 2005, 6:815-820.
3. Johnson ES. Protein modification by SUMO. Annu Rev Biochem 2004, 73:355-382.
4. Wang J, Schwartz RJ. Sumoylation and regulation of cardiac gene expression. Circ Res 2010, 107:19-29.
5. Jeon YJ, Yoo HM, Chung CH. ISG15 and immune diseases. Biochim Biophys Acta 2010, 1802:485-496.
6. D'Cunha J, Knight E Jr, Haas AL, Truitt RL, Borden EC. Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci U S A 1996, 93:211-215.
7. Nakamura M, Tanigawa Y. Ubiquitin-like polypeptide inhibits cAMP-induced p38 MAPK activation in Th2 cells. Immunobiology 2004, 208:439-444.
8. Nakamura M, Shimosaki S. The ubiquitin-like protein monoclonal nonspecific suppressor factor β conjugates to endophilin II and regulates phagocytosis. FEBS J 2009, 276:6355-6363.
9. Hipp MS, Kalveram B, Raasi S, Groettrup M, Schmidtke G. FAT10, a ubiquitin-independent signal for proteasomal degradation. Mol Cell Biol 2005, 25: 3483-3491.
10. Snyder A, Alsauskas Z, Gong P, Rosenstiel PE, Klotman ME, Klotman PE, Ross MJ. FAT10: a novel mediator of Vpr-induced apoptosis in human immunodeficiency virus-associated nephropathy. J Virol 2009, 83:11983-11988.
11. Raasi S, Schmidtke G, Groettrup M. The ubiquitinlike protein FAT10 forms covalent conjugates and induces apoptosis. J Biol Chem 2001, 276: 35334-35343.
12. Rabut G, Peter M. Function and regulation of protein neddylation. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 2008, 9:969-976.
13. Komatsu M, Chiba T, Tatsumi K, Iemura S, Tanida I, Okazaki N, Ueno T, Kominami E, Natsume T, Tanaka K. A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. EMBO J 2004, 23: 1977-1986.
14. Geng J, Klionsky DJ. The Atg8 and Atg12 ubiquitinlike conjugation systems in macroautophagy. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 2008, 9:859-864.
15. Pedrioli PG, Leidel S, Hofmann K. Urm1 at the crossroad of modifications. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 2008, 9:1196-1202.
16. Leidel S, Pedrioli PG, Bucher T, Brost R, Costanzo M, Schmidt A, Aebersold R, Boone C, Hofmann K, Peter M. Ubiquitin-related modifier Urm1 acts as a sulphur carrier in thiolation of eukaryotic transfer RNA. Nature 2009, 458:228-232.
17. Benedetti C, Haynes CM, Yang Y, Harding HP, Ron D. Ubiquitin-like protein 5 positively regulates chaperone gene expression in the mitochondrial unfolded protein response. Genetics 2006, 174: 229-239.
18. Downes BP, Saracco SA, Lee SS, Crowell DN, Vierstra RD. MUBs, a family of ubiquitin-fold proteins that are plasma membrane-anchored by prenylation. J Biol Chem2006, 281:27145-27157.
19. Dohmen RJ. SUMO protein modification. Biochim Biophys Acta 2004, 1695:113-131.
20. Melchior F. SUMO-nonclassical ubiquitin. Annu Rev Cell Dev Biol 2000, 16:591-626.
21. Xu Z, Chan HY, Lam WL, Lam KH, Lam LS, Ng TB, Au SW. SUMO proteases: redox regulation and biological consequences. Antioxid Redox Signal 2009, 11:1453-1484.
22. Muller S, Hoege C, Pyrowolakis G, Jentsch S. SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol 2001, 2:202-210.
23. Rodriguez MS, Dargemont C, Hay RT. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem 2001, 276:12654-12659.
24. Johnson ES, Blobel G. Cell cycle-regulated attachment of the ubiquitin-related protein SUMO to the yeast septins. J Cell Biol 1999, 147:981-994.
25. Chen A, Mannen H, Li SS. Characterization of mouse ubiquitin-like SMT3A and SMT3B cDNAs and gene/pseudogenes. Biochem Mol Biol Int 1998, 46: 1161-1174.
26. Saitoh H, Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 2000, 275:6252-6258.
27. Bohren KM, Nadkarni V, Song JH, Gabbay KH, Owerbach D. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J Biol Chem 2004, 279:27233-27238.
28. Xu Z, Au SW. Mapping residues of SUMO precursors essential in differential maturation by SUMO-specific protease, SENP1. Biochem J 2005, 386:325-330.
29. Owerbach D, McKay EM, Yeh ET, Gabbay KH, Bohren KM. A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun 2005, 337:517-520.
30. Shao R, Zhang FP, Tian F, Anders Friberg P, Wang X, Sjoland H, Billig H. Increase of SUMO-1 expression in response to hypoxia: direct interaction with HIF-1α in adult mouse brain and heart in vivo. FEBS Lett 2004, 569:293-300.
31. Ayaydin F, Dasso M. Distinct in vivo dynamics of vertebrate SUMO paralogues. Mol Biol Cell 2004, 15:5208-5218.
32. Zhang XD, Goeres J, Zhang H, Yen TJ, Porter AC, Matunis MJ. SUMO-2/3 modification and binding regulate the association of CENP-E with kinetochores and progression through mitosis. Mol Cell 2008, 29: 729-741.
33. Pichler A, Gast A, Seeler JS, Dejean A, Melchior F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 2002, 108:109-120.
34. Kagey MH, Melhuish TA, Wotton D. The polycomb protein Pc2 is a SUMO E3. Cell 2003, 113:127-137.
35. Rytinki MM, Kaikkonen S, Pehkonen P, Jaaskelainen T, Palvimo JJ. PIAS proteins: pleiotropic interactors associated with SUMO. Cell Mol Life Sci 2009, 66:3029-3041.
36. Weger S, Hammer E, Heilbronn R. Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo. FEBS Lett 2005, 579:5007-5012.
37. Pungaliya P, Kulkarni D, Park HJ, Marshall H, Zheng H, Lackland H, Saleem A, Rubin EH. TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteins. J Proteome Res 2007, 6:3918-3923.
38. Morita Y, Kanei-Ishii C, Nomura T, Ishii S. TRAF7 sequesters c-Myb to the cytoplasm by stimulating its sumoylation. Mol Biol Cell 2005, 16:5433-5444.
39. Braschi E, Zunino R, McBride HM. MAPL is a new mitochondrial SUMO E3 ligase that regulates mitochondrial fission. EMBO Rep 2009, 10:748-754.
40. Subramaniam S, Sixt KM, Barrow R, Snyder SH. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009, 324:1327-1330.
41. Kotaja N, Karvonen U, Janne OA, Palvimo JJ. PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol Cell Biol 2002, 22: 5222-5234.
42. Deng Z, Wan M, Sui G. PIASy-mediated sumoylation of Yin Yang 1 depends on their interaction but not the RING finger. Mol Cell Biol 2007, 27:3780-3792.
43. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, et al. A physical and functional map of the human TNF-α/NF-κ B signal transduction pathway. Nat Cell Biol 2004, 6:97-105.
44. Kirsh O, Seeler JS, Pichler A, Gast A, Muller S, Miska E, Mathieu M, Harel-Bellan A, Kouzarides T, Melchior F, et al. The SUMO E3 ligase RanBP2 promotesmodification of the HDAC4deacetylase. EMBO J 2002, 21:2682-2691.
45. Dawlaty MM, Malureanu L, Jeganathan KB, Kao E, Sustmann C, Tahk S, Shuai K, Grosschedl R, van Deursen JM. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIα. Cell 2008, 133:103-115.
46. Wang J, Feng XH, Schwartz RJ. SUMO-1 modification activated GATA4-dependent cardiogenic gene activity. J Biol Chem 2004, 279:49091-49098.
47. Subramaniam S, Mealer RG, Sixt KM, Barrow RK, Usiello A, Snyder SH. RHES, a physiologic regulator of sumoylation, enhances cross-sumoylation among the basic sumoylation enzymes E1 and UBC9. J Biol Chem 2010, 285:20428-20432.
48. Yeh ET. SUMOylation and de-SUMOylation: wrestling with life's processes. J Biol Chem 2008, 284: 8223-8227.
49. Hay RT. SUMO-specific proteases: a twist in the tail. Trends Cell Biol 2007, 17:370-376.
50. Gong L, Millas S, Maul GG, Yeh ET. Differential regulation of sentrinized proteins by a novel sentrinspecific protease. J Biol Chem 2000, 275:3355-3359.
51. Gong L, Yeh ET. Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3. J Biol Chem 2006, 281: 15869-15877.
52. Di Bacco A, Ouyang J, Lee HY, Catic A, Ploegh H, Gill G. The SUMO-specific protease SENP5 is required for cell division. Mol Cell Biol 2006, 26:4489-4498.
53. Mukhopadhyay D, Ayaydin F, Kolli N, Tan SH, Anan T, Kametaka A, Azuma Y, Wilkinson KD, Dasso M. SUSP1 antagonizes formation of highly SUMO2/3-conjugated species. J Cell Biol 2006, 174:939-949.
54. Shen LN, Geoffroy MC, Jaffray EG, Hay RT. Characterization of SENP7, a SUMO-2/3-specific isopeptidase. Biochem J 2009, 421:223-230.
55. Cheng J, Kang X, Zhang S, Yeh ET. SUMO-specific protease 1 is essential for stabilization ofHIF1α during hypoxia. Cell 2007, 131:584-595.
56. Kang X, Qi Y, Zuo Y, Wang Q, Zou Y, Schwartz RJ, Cheng J, Yeh ET. SUMO-specific protease 2 is essential for suppression of polycomb group proteinmediated gene silencing during embryonic development. Mol Cell 2010, 38:191-201.
57. Chiu SY, Asai N, Costantini F, Hsu W. SUMOspecific protease 2 is essential for modulating p53-Mdm2 in development of trophoblast stem cell niches and lineages. PLoS Biol 2008, 6:e310.
58. Matunis MJ, Coutavas E, Blobel G. A novel ubiquitinlike modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J CellBiol 1996, 135:1457-1470.
59. Lin X, Sun B, Liang M, Liang YY, Gast A, Hildebrand J, Brunicardi FC, Melchior F, Feng XH. Opposed regulation of corepressor CtBP by SUMOylation and PDZ binding. Mol Cell 2003, 11:1389-1396.
60. Goodson ML, Hong Y, Rogers R, Matunis MJ, Park-Sarge OK, Sarge KD. Sumo-1 modification regulatesthe DNA binding activity of heat shock transcription factor 2, a promyelocytic leukemia nuclear body associated transcription factor. J Biol Chem 2001, 276:18513-18518.
61. Thakar K, Niedenthal R, Okaz E, Franken S, Jakobs A, Gupta S, Kelm S, Dietz F. SUMOylation of the hepatoma-derived growth factor negatively influences its binding to chromatin. Febs J 2008, 275:1411-1426.
62. Oshima M, Mimura J, Sekine H, Okawa H, Fujii-Kuriyama Y. SUMO modification regulates the transcriptional repressor function of aryl hydrocarbon receptor repressor. J Biol Chem 2009, 284: 11017-11026.
63. Kerscher O. SUMO junction-what's your function? New insights through SUMO-interacting motifs. EMBO Rep 2007, 8:550-555.
64. Parnas O, Zipin-Roitman A, Pfander B, Liefshitz B, Mazor Y, Ben-Aroya S, Jentsch S, Kupiec M. Elg1, an alternative subunit of the RFC clamp loader, preferentially interacts with SUMOylated PCNA. EMBO J 2010, 29:2611-2622.
65. Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IκBα inhibits NF-κB activation. Mol Cell 1998, 2:233-239.
66. Sharma P, Murillas R, Zhang H, Kuehn MR. N4BP1 is a newly identified nucleolar protein that undergoes SUMO-regulated polyubiquitylation and proteasomal turnover at promyelocytic leukemia nuclear bodies. J Cell Sci 2010, 123:1227-1234.
67. Wang J, Zhang H, Iyer D, Feng XH, Schwartz RJ. Regulation of cardiac specific Nkx2.5 gene activity by SUMO modification. J Biol Chem 2008, 283:23235-23243.
68. Prudden J, Pebernard S, Raffa G, Slavin DA, Perry JJ, Tainer JA, McGowan CH, Boddy MN. SUMOtargeted ubiquitin ligases in genome stability. EMBO J 2007, 26:4089-4101.
69. Le Drean Y, Mincheneau N, Le Goff P, Michel D. Potentiation of glucocorticoid receptor transcriptional activity by sumoylation. Endocrinology 2002, 143:3482-3489.
70. Bae SH, Jeong JW, Park JA, Kim SH, Bae MK, Choi SJ, Kim KW. Sumoylation increases HIF-1α stability and its transcriptional activity. Biochem Biophys Res Commun 2004, 324:394-400.
71. Carbia-Nagashima A, Gerez J, Perez-Castro C, Paez-Pereda M, Silberstein S, Stalla GK, Holsboer F, Arzt E. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1α during hypoxia. Cell 2007, 131:309-323.
72. Berta MA, Mazure N, Hattab M, Pouyssegur J, Brahimi-Horn MC. SUMOylation of hypoxia-inducible factor-1α reduces its transcriptional activity. Biochem Biophys Res Commun 2007, 360:646-652.
73. Komatsu T, Mizusaki H, Mukai T, Ogawa H, Baba D, Shirakawa M, Hatakeyama S, Nakayama KI, Yamamoto H, Kikuchi A, et al. SUMO-1modification of the synergy control motif of Ad4BP/SF-1 regulates synergistic transcription between Ad4BP/SF-1 and Sox9. Mol Endocrinol 2004, 18:2451-2462.
74. Matsuzaki K, Minami T, Tojo M, Honda Y, Uchimura Y, Saitoh H, Yasuda H, Nagahiro S, Saya H, Nakao M. Serum response factor is modulated by the SUMO-1 conjugation system. Biochem Biophys Res Commun 2003, 306:32-38.
75. Wang J, Li A, Wang Z, Feng X, Olson EN, Schwartz RJ. Myocardin sumoylation transactivates cardiogenic genes in pluripotent 10T1/2 fibroblasts. Mol Cell Biol 2007, 27:622-632.
76. Pan MR, Chang TM, Chang HC, Su JL, Wang HW, Hung WC. Sumoylation of Prox1 controls its ability to induce VEGFR3 expression and lymphatic phenotypes in endothelial cells. J Cell Sci 2009, 122:3358-3364.
77. Shan SF, Wang LF, Zhai JW, Qin Y, Ouyang HF, Kong YY, Liu J, Wang Y, Xie YH. Modulation of transcriptional corepressor activity of prospero-related homeobox protein (Prox1) by SUMO modification. FEBS Lett 2008, 582:3723-3728.
78. Wang J. SUMO conjugation and cardiovascular development. Front Biosci 2009, 14:1219-1229.
79. Rytinki MM, Palvimo JJ. SUMOylation attenuates the function of PGC-1α. J Biol Chem 2009, 284: 26184-26193.
80. Leuenberger N, Pradervand S, Wahli W. Sumoylated PPARα mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice. J Clin Invest 2009, 119:3138-3148.
81. Pourcet B, Pineda-Torra I, Derudas B, Staels B, Glineur C. SUMOylation of human peroxisome proliferator-activated receptor α inhibits its trans-activity through the recruitment of the nuclear corepressor NCoR. J Biol Chem2010, 285:5983-5992.
82. Ohshima T, Koga H, Shimotohno K. Transcriptional activity of peroxisome proliferator-activated receptor-α is modulated by SUMO-1 modification. J BiolChem 2004, 279:29551-29557.
83. Yamashita D, Yamaguchi T, Shimizu M, Nakata N, Hirose F, Osumi T. The transactivating function of peroxisome proliferator-activated receptor γ is negatively regulated by SUMO conjugation in the aminoterminal domain. Genes Cells 2004, 9: 1017-1029.
84. Vu EH, Kraus RJ, Mertz JE. Phosphorylationdependent sumoylation of estrogen-related receptor α1. Biochemistry 2007, 46:9795-9804.
85. Harder Z, Zunino R, McBride H. Sumo1 conjugates mitochondrial substrates and participates inmitochondrial fission. Curr Biol 2004, 14:340-345.
86. Woo CH, Shishido T, McClain C, Lim JH, Li JD, Yang J, Yan C, Abe J. Extracellular signal-regulatedkinase 5 SUMOylation antagonizes shear stressinduced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells. Circ Res 2008, 102:538-545.
87. Martin N, Schwamborn K, Schreiber V, Werner A, Guillier C, Zhang XD, Bischof O, Seeler JS, Dejean A. PARP-1 transcriptional activity is regulated by sumoylation upon heat shock. EMBO J 2009, 28:3534-3548.
88. Messner S, Schuermann D, Altmeyer M, Kassner I, Schmidt D, Schar P, Muller S, Hottiger MO. Sumoylation of poly(ADP-ribose) polymerase 1 inhibits its acetylation and restrains transcriptional coactivator function. FASEB J 2009, 23:3978-3989.
89. Kruse M, Schulze-Bahr E, Corfield V, Beckmann A, Stallmeyer B, Kurtbay G, Ohmert I, Brink P, Pongs O. Impaired endocytosis of the ion channel TRPM4 is associated with human progressive familial heart block type I. J Clin Invest 2009, 119:2737-2744.
90. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP. Peroxisome proliferator-activated receptor γ coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 2000, 106: 847-856.
91. Sihag S, Cresci S, Li AY, Sucharov CC, Lehman JJ. PGC-1α and ERRα target gene downregulation is a signature of the failing human heart. J Mol Cell Cardiol 2009, 46:201-212.
92. Russell LK, Mansfield CM, Lehman JJ, Kovacs A, Courtois M, Saffitz JE, Medeiros DM, Valencik ML, McDonald JA, Kelly DP. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor γ coactivator-1α promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res 2004, 94:525-533.
93. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, et al. PGC-1α deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 2005, 3:e101.
94. Zhong N, Xu J. Synergistic activation of the human MnSOD promoter by DJ-1 and PGC-1α: regulation by SUMOylation and oxidation. Hum Mol Genet 2008, 17:3357-3367.
95. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996, 37:907-925.
96. Hardwick JP, Osei-Hyiaman D, Wiland H, Abdelmegeed MA, Song BJ. PPAR/RXR regulation of fatty acid metabolism and fatty acid α-hydroxylase (CYP4) isozymes: implications for prevention of lipotoxicity in fatty liver disease. PPAR Res 2009, 2009:952734.
97. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JR, Belke DD, Severson DL, Kelly DP, Lopaschuk GD. A role for peroxisome proliferator-activated receptor α (PPARα) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARα are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 2002, 277:4098-4103.
98. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, et al. The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002, 109:121-130.
99. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, et al. Cardiomyocyte-restricted peroxisome proliferatoractivated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004, 10:1245-1250.
100. Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-γ both induce cardiac hypertrophy in mice. Circ Res 2005, 97:372-379.
101. Vanacker JM, Delmarre C, Guo X, Laudet V. Activation of the osteopontin promoter by the orphan nuclear receptor estrogen receptor related α. Cell Growth Differ 1998, 9:1007-1014.
102. Vanacker JM, Bonnelye E, Delmarre C, Laudet V. Activation of the thyroid hormone receptor α gene promoter by the orphan nuclear receptor ERR α. Oncogene 1998, 17:2429-2435.
103. Huss JM, Imahashi K, Dufour CR, Weinheimer CJ, Courtois M, Kovacs A, Giguere V, Murphy E, Kelly DP. The nuclear receptor ERRα is required for the bioenergetic and functional adaptation to cardiac pressure overload. Cell Metab 2007, 6:25-37.
104. Figueroa-Romero C, Iniguez-Lluhi JA, Stadler J, Chang CR, Arnoult D, Keller PJ, Hong Y, Blackstone C, Feldman EL. SUMOylation of the mitochondrial fission protein Drp1 occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycle. FASEB J 2009, 23:3917-3927.
105. Wasiak S, Zunino R, McBride HM. Bax/Bak promote sumoylation of DRP1 and its stable association with mitochondria during apoptotic cell death. J Cell Biol 2007, 177:439-450.
106. Zunino R, Schauss A, Rippstein P, Andrade-Navarro M, McBride HM. The SUMO protease SENP5 is required to maintain mitochondrial morphology and function. J Cell Sci 2007, 120:1178-1188.
107. Dai XQ, Kolic J, Marchi P, Sipione S, Macdonald PE. SUMOylation regulates Kv2.1 and modulates pancreatic α-cell excitability. J Cell Sci 2009, 122: 775-779.
108. Benson MD, Li QJ, Kieckhafer K, Dudek D, Whorton MR, Sunahara RK, Iniguez-Lluhi JA, Martens JR. SUMO modification regulates inactivation of thevoltage-gated potassium channel Kv1.5. Proc Natl Acad Sci U S A 2007, 104:1805-1810.
109. Rajan S, Plant LD, Rabin ML, Butler MH, Goldstein SA. Sumoylation silences the plasma membrane leak K+ channel K2P1. Cell 2005, 121:37-47.
110. Rougier JS, Albesa M, Abriel H. Ubiquitylation and SUMOylation of cardiac ion channels. J Cardiovasc Pharmacol 2010, 56:22-28.
111. Woo CH, Massett MP, Shishido T, Itoh S, Ding B, McClain C, Che W, Vulapalli SR, Yan C, Abe J. ERK5 activation inhibits inflammatory responses via peroxisome proliferator-activated receptor α (PPARα) stimulation. J Biol Chem 2006, 281: 32164-32174.
112. Pacher P, Szabo C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev 2007, 25:235-260.
113. Pauws E, Stanier P. FGF signalling and SUMO modification: new players in the aetiology of cleft lip and/or palate. Trends Genet 2007, 23:631-640.
114. Song T, Li G, Jing G, Jiao X, Shi J, Zhang B, Wang L, Ye X, Cao F. SUMO1 polymorphisms are associated with non-syndromic cleft lip with or without cleft palate. Biochem Biophys Res Commun 2008, 377:1265-1268.
115. Dorval V, Fraser PE. SUMO on the road to neurodegeneration. Biochim Biophys Acta 2007, 1773: 694-706.
116. Wu F, Mo YY. Ubiquitin-like protein modifications in prostate and breast cancer. Front Biosci 2007, 12: 700-711.
117. van Tintelen JP, van Spaendonck-Zwarts KY, van den Berg MP. Lamin A/C-related cardiac disease and pregnancy. Eur J Heart Fail 2010, 12:532-534.
118. Zhang YQ, Sarge KD. Sumoylation regulates lamin A function and is lost in lamin A mutants associated with familial cardiomyopathies. J Cell Biol 2008, 182:35-39.
119. Sarge KD, Park-Sarge OK. Sumoylation and human disease pathogenesis. Trends Biochem Sci 2009, 34: 200-205.
120. Pattison JS, Robbins J. Protein misfolding and cardiac disease: establishing cause and effect. Autophagy 2008, 4:821-823.
121. Pattison JS, Sanbe A, Maloyan A, Osinska H, Klevitsky R, Robbins J. Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. Circulation 2008, 117:2743-2751.
122. Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N, Illes K, Lukacsovich T, Zhu YZ, Cattaneo E, et al. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004, 304:100-104.
123. Riley BE, Zoghbi HY, Orr HT. SUMOylation of the polyglutamine repeat protein, ataxin-1, is dependent on a functional nuclear localization signal. J BiolChem 2005, 280:21942-21948.
124. Mukherjee S, Thomas M, Dadgar N, Lieberman AP, Iniguez-Lluhi JA. Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation. J BiolChem 2009, 284:21296-21306.
125. Zhang YQ, Sarge KD. Sumoylation of amyloid precursor protein negatively regulates Aα aggregate levels. Biochem Biophys Res Commun 2008, 374:673-678.
126. Ueda H, Goto J, Hashida H, Lin X, Oyanagi K, Kawano H, Zoghbi HY, Kanazawa I, Okazawa H. Enhanced SUMOylation in polyglutamine diseases. Biochem Biophys Res Commun 2002, 293:307-313.
127. Liu H, El Zein L, Kruse M, Guinamard R, Beckmann A, Bozio A, Kurtbay G, Megarbane A, Ohmert I, Blaysat G, et al. Gain-of-function mutations in TRPM4 cause autosomal dominant isolated cardiac conduction disease. Circ Cardiovasc Genet 2010, 3: 374-385.